Actualizado 08/12/2010 21:05
- Comunicado -

European Approval for SPRYCEL(R) (dasatinib) in Adult Patients With Newly Diagnosed CML: First New Approved Treatment in

CONTACT: Contact: Bristol-Myers Squibb, European Media Contact: ElzbietaZawislak, +33615523580, elzbieta.zawislak@bms.com .

Contenido patrocinado